Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.

McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS.

Pract Radiat Oncol. 2018 Apr 26. pii: S1879-8500(18)30142-5. doi: 10.1016/j.prro.2018.04.012. [Epub ahead of print]

PMID:
29937235
2.

Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.

Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1222-1225. doi: 10.1016/j.ijrobp.2018.04.026. Epub 2018 Apr 17.

PMID:
29859792
3.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

PMID:
29800971
4.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

5.

Recent progress in systemic treatment for lung cancer.

Clark JW, Longo DL.

Curr Opin Pulm Med. 2018 Jul;24(4):355-366. doi: 10.1097/MCP.0000000000000493.

PMID:
29697418
6.

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Weekes CD, Clark JW, Zhu AX.

Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3. No abstract available.

PMID:
29625880
7.

The timescale of early land plant evolution.

Morris JL, Puttick MN, Clark JW, Edwards D, Kenrick P, Pressel S, Wellman CH, Yang Z, Schneider H, Donoghue PCJ.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2274-E2283. doi: 10.1073/pnas.1719588115. Epub 2018 Feb 20.

8.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
9.

Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX.

Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.

Ann Surg. 2017 Dec 7. doi: 10.1097/SLA.0000000000002600. [Epub ahead of print]

PMID:
29227344
10.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
11.

Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.

Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460. doi: 10.1073/pnas.1710754114. Epub 2017 Sep 12.

12.

Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.

Miller CL, Taylor MS, Qadan M, Deshpande V, Worthington S, Smalley R, Collura C, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Parikh AR, Berger D, Tanabe KK, Lillemoe KD, Ferrone CR.

J Gastrointest Surg. 2017 Nov;21(11):1831-1840. doi: 10.1007/s11605-017-3557-0. Epub 2017 Sep 7.

PMID:
28884391
13.

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.

Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY.

Adv Radiat Oncol. 2017 Feb 6;2(2):110-117. doi: 10.1016/j.adro.2017.01.009. eCollection 2017 Apr-Jun.

14.

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Jung K, Heishi T, Khan OF, Kowalski PS, Incio J, Rahbari NN, Chung E, Clark JW, Willett CG, Luster AD, Yun SH, Langer R, Anderson DG, Padera TP, Jain RK, Fukumura D.

J Clin Invest. 2017 Aug 1;127(8):3039-3051. doi: 10.1172/JCI93182. Epub 2017 Jul 10.

15.

Constraining the timing of whole genome duplication in plant evolutionary history.

Clark JW, Donoghue PCJ.

Proc Biol Sci. 2017 Jul 12;284(1858). pii: 20170912. doi: 10.1098/rspb.2017.0912.

16.

Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS.

Br J Radiol. 2017 Aug;90(1076):20170134. doi: 10.1259/bjr.20170134. Epub 2017 Jun 14.

PMID:
28613934
17.

Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.

Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK.

Clin Cancer Res. 2017 Oct 1;23(19):5959-5969. doi: 10.1158/1078-0432.CCR-17-0256. Epub 2017 Jun 9.

PMID:
28600474
18.

Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.

Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e291-e297. doi: 10.1016/j.prro.2017.03.008. Epub 2017 Mar 23.

PMID:
28462895
19.

Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.

Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS.

Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349.

PMID:
28134673
20.

Limits to Precision Cancer Medicine.

Clark JW, Chabner BA.

N Engl J Med. 2017 Jan 5;376(1):96. doi: 10.1056/NEJMc1613563. No abstract available.

PMID:
28052223
21.

Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.

Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-Del Castillo C.

Pancreas. 2017 Feb;46(2):183-189. doi: 10.1097/MPA.0000000000000731.

PMID:
27846142
22.

Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.

Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS.

Am J Clin Oncol. 2018 Jun;41(6):607-612. doi: 10.1097/COC.0000000000000336.

PMID:
27740973
23.

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK, Fukumura D.

Sci Transl Med. 2016 Oct 12;8(360):360ra135.

24.

Effects of Mental Health and Neuroscience Evidence on Juror Perceptions of a Criminal Defendant: the Moderating Role of Political Orientation.

Mowle EN, Edens JF, Clark JW, Sörman K.

Behav Sci Law. 2016 Nov;34(6):726-741. doi: 10.1002/bsl.2251. Epub 2016 Sep 13.

PMID:
27620269
25.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.

J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.

26.

One American Perspective on the Rights of Accused: An Initial Survey of Miranda Rights in a Broader Context.

Rogers R, Sharf AJ, Clark JW 3rd, Drogin EY, Winningham DB, Williams MM.

Behav Sci Law. 2016 Jul;34(4):477-94. doi: 10.1002/bsl.2240. Epub 2016 May 23.

PMID:
27213849
27.

A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.

Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER.

Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044. Epub 2016 Mar 31.

28.

A protein and mRNA expression-based classification of gastric cancer.

Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY.

Mod Pathol. 2016 Jul;29(7):772-84. doi: 10.1038/modpathol.2016.55. Epub 2016 Apr 1.

29.

"A Psychopath by Any Other Name?": Juror Perceptions of the DSM-5 "Limited Prosocial Emotions" Specifier.

Edens JF, Mowle EN, Clark JW, Magyar MS.

J Pers Disord. 2017 Feb;31(1):90-109. doi: 10.1521/pedi_2016_30_239. Epub 2016 Mar 9.

PMID:
26959961
30.

Boldness and its relation to psychopathic personality: Prototypicality analyses among forensic mental health, criminal justice, and layperson raters.

Sörman K, Edens JF, Smith ST, Clark JW, Kristiansson M, Svensson O.

Law Hum Behav. 2016 Jun;40(3):337-49. doi: 10.1037/lhb0000176. Epub 2016 Feb 4.

PMID:
26844911
31.

The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.

Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT.

J Surg Oncol. 2016 Apr;113(5):560-4. doi: 10.1002/jso.24179. Epub 2016 Jan 21.

PMID:
26792144
32.

On the roles of vascular smooth muscle contraction in cerebral blood flow autoregulation - a modeling perspective.

Jin Yang, Clark JW.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7796-9. doi: 10.1109/EMBC.2015.7320200. Review.

PMID:
26738100
33.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX.

J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.

34.

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM.

J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.

PMID:
26553764
35.

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB.

Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. Erratum in: Cancer Discov. 2016 Dec;6(12 ):1402.

36.

Familial Gastric Cancers.

Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY.

Oncologist. 2015 Dec;20(12):1365-77. doi: 10.1634/theoncologist.2015-0205. Epub 2015 Sep 30. Review.

37.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

38.

Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach.

Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT.

J Gastrointest Surg. 2016 Jan;20(1):172-9; discussion 179. doi: 10.1007/s11605-015-2954-5. Epub 2015 Sep 22.

PMID:
26394879
39.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

40.

Dictionary learning for data recovery in positron emission tomography.

Valiollahzadeh S, Clark JW, Mawlawi O.

Phys Med Biol. 2015 Aug 7;60(15):5853-71. doi: 10.1088/0031-9155/60/15/5853. Epub 2015 Jul 10.

41.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

42.

Using compressive sensing to recover images from PET scanners with partial detector rings.

Valiollahzadeh S, Clark JW Jr, Mawlawi O.

Med Phys. 2015 Jan;42(1):121-33. doi: 10.1118/1.4903291.

43.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

44.

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Dahlberg SE, Shapiro GI, Clark JW, Johnson BE.

J Natl Cancer Inst. 2014 Jun 24;106(7). pii: dju163. doi: 10.1093/jnci/dju163. Print 2014 Jul.

PMID:
24963024
45.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

46.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

47.

Merging of Landau levels in a strongly interacting two-dimensional electron system in silicon.

Shashkin AA, Dolgopolov VT, Clark JW, Shaginyan VR, Zverev MV, Khodel VA.

Phys Rev Lett. 2014 May 9;112(18):186402. Epub 2014 May 8.

PMID:
24856708
48.

A mock juror investigation of blame attribution in the punishment of hate crime perpetrators.

Cramer RJ, Clark JW 3rd, Kehn A, Burks AC, Wechsler HJ.

Int J Law Psychiatry. 2014 Nov-Dec;37(6):551-7. doi: 10.1016/j.ijlp.2014.02.028. Epub 2014 Mar 22.

PMID:
24666730
49.

Why the impact? Negative affective change as a mediator of the effects of victim impact statements.

Wevodau AL, Cramer RJ, Kehn A, Clark JW 3rd.

J Interpers Violence. 2014 Nov;29(16):2884-903. doi: 10.1177/0886260514527170. Epub 2014 Mar 24.

PMID:
24664251
50.

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):323-6; quiz 326.

PMID:
24616538

Supplemental Content

Loading ...
Support Center